Press Releases

June 23, 2016

Edison Pharmaceuticals Announces Positive Results from Phase 2 Placebo-Controlled EPI-743 Leigh Syndrome Trial

Edison Pharmaceuticals Announces Positive Results from Phase 2 Placebo-Controlled EPI-743 Leigh Syndrome Trial

September 3, 2014

Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome

June 9, 2014

FDA Grants Edison Pharmaceuticals’ EPI-743 Orphan Status for Leigh Syndrome

May 20, 2014

Edison Pharmaceuticals’ EPI-743 Granted Orphan Designation for Leigh Syndrome in Japan

March 17, 2014

FDA Awards Fast Track Status to Edison Pharmaceuticals’ EPI-743 for Friedreich’s Ataxia

March 17, 2014

Edison Pharmaceuticals Announces Initiation of EPI-743 Pearson Syndrome Clinical Trial

March 13, 2014

Edison Announces Initiation of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co. Ltd. in Japan

January 31, 2014

Edison Pharmaceuticals, Inc. enters into strategic alliance with Dainippon Sumitomo Pharma Co., Ltd. Novel partnership in drugs targeting biological energy Mountain View, CA. January 31, 2014. Edison Pharmaceuticals today announced that it has entered into a strategic alliance valued up to $4.295 billion with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of drugs […]

Edison Pharmaceuticals, Inc. enters into strategic alliance with Dainippon Sumitomo Pharma Co., Ltd.

November 4, 2013

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2 Friedreich’s Ataxia Point Mutation Clinical Trial

September 24, 2013

Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients

March 28, 2013

Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd

February 19, 2013

Edison Pharmaceuticals & Bambino Gesu Children’s Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial

January 7, 2013

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich’s Ataxia Clinical Trial

November 13, 2012

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial

September 12, 2012

EMA Grants EPI-743 Orphan Designation

September 13, 2011

Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial

September 13, 2011

Edison Pharmaceuticals, Inc. closes financing

June 8, 2011

Edison Pharmaceuticals licenses drug from Centocor for rare diseases